By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Aventis Pharma S.A. et al. v. Hospira, Inc.
2:07-cv-08137; filed December 14, 2007 in the Central District of California
Infringement of U.S. Patent No. RE38,743 ("Mixtures of Particular LMW Heparinic Polysaccharides for the Prophylaxis/Treatment of Acute Thrombotic Events," issued June 14, 2005; reissue of U.S. Patent No. 5,389,618) following a paragraph IV certification as part of Hospira's filing of an ANDA to manufacture a generic version of Aventis' Lovenox® (enoxaparin sodium injection, used for the prophylaxis and treatment of thromboembolic disease). View the complaint here. [NB: In an earlier case the '743 patent was held unenforceable; that decision is currently pending on appeal with the Federal Circuit.]
Sciele Pharma Inc. et al. v. Mylan Pharmaceuticals Inc. et al.
1:07-cv-00818; filed December 14, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 4,892,741 ("Press coated DHP tablets," issued January 9, 1990) following a paragraph IV certification as part of Mylan's amendment of their ANDA (adding additional dosage forms) to manufacture a generic version of Sciele's Sular® (nisoldipine, used to treat hypertension). View the complaint here. As reported here, Sciele has previously asserted this patent against Mylan in response to Mylan's initial paragraph IV certification.
Duramed Pharmaceuticals, Inc. v. Sandoz Inc.
3:07-cv-05940; filed December 13, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. RE39,861 ("Methods of Extended Use Oral Contraception," issued September 25, 2007) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Duramed's Seasonale® (estrogen and progestin, used for oral contraception). View the complaint here.
Duramed Pharmaceuticals, Inc. v. Watson Pharma, Inc. et al.
3:07-cv-05941; filed December 13, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. RE39,861 ("Methods of Extended Use Oral Contraception," issued September 25, 2007) based on Watson's manufacture and sale of its Quasense®, allegedy a generic version of Duramed's Seasonale® (estrogen and progestin, used for oral contraception). View the complaint here.
Pfizer Inc. et al. v. Teva Pharmaceuticals USA, Inc.
1:07-cv-11198; filed December 12, 2007 in the Southern District of New York
Infringement of U.S. Patent Nos. 5,382,600 ("3,3-Diphenylpropylamines and Pharmaceutical Compositions Thereof, issued January 17, 1995), 6,630,162 ("Pharmaceutical Formulation and Its Use," issued October 7, 2003), and 6,770,295 ("Therapeutic Formulation for Administering Tolterodine with Controlled Release," issued August 3, 2004) following a paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Pfizer's Detrol LA® (extended release tolterodine tartrate, used to treat overactive bladder). View the complaint here.
Novartis Corporation et al. v. Mylan Laboratories Inc. et al.
2:07-cv-05930; filed December 11, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,162,802 ("Synergistic Combination Therapy Using Benazepril and Amlodipine for the Treatment of Cardiovascular Disorders and Compositions Therefor," issued December 19, 2000) following a second paragraph IV notification letter stating that Mylan's ANDA to manufacture a generic version of Novartis' Lotrel® (amlodipine besylate/benazepril hydrochloride, used to treat hypertension) was directed to an additional dosage form not mentioned in the initial notification letter. View the complaint here. Novartis previously filed suit against Mylan in response to the initial notification letter as reported here.
Note to our Readers: Court Report is being presented in two parts this week. Part II will be posted tomorrow.
Comments